Ionis is no longer being priced as a royalty platform waiting on a cardiovascular outcomes lottery. Partner Novartis said pelacarsen lowered lipoprotein(a) in a large outcomes study and still failed to cut major heart events versus placebo. That readout landed the same week regulators cleared ZANVASTRO for Alexander disease, the company's first wholly owned neurology launch and its third independent product after TRYNGOLZA and DAWNZERA. The equity is now a commercial-execution story with two partnered outcome misses already booked and a still-lumpy research-collaboration profit-and-loss statement.
The June quarter printed total revenue of $268 million, down from a year-ago print that included a $280 million Ono upfront. Commercial revenue rose to $119 million. Product sales were $31 million, almost all DAWNZERA after a planned TRYNGOLZA price cut. Cash and short-term investments were $2.1 billion after the company repaid the April convert. Guidance still calls for full-year revenue of $875 million to $900 million. Management still points to cash-flow breakeven later this decade.
The investment question is whether TRYNGOLZA's severe-hypertriglyceridemia launch and DAWNZERA's hereditary-angioedema switch share can replace the partnered-outcomes optionality the market just deleted. A mid-September quoted close near $47 is the working mark for this report. That price implies equity value of about $7.8 billion. The share count is roughly 166 million. That is a high-single-digit sales multiple on this year's revenue guide, with net cash thin once converts and the royalty-sale liability are counted. If owned-product growth compounds, the multiple is a launch-year entry. If it does not, the stock is still a cash-burning platform with fewer lottery tickets.